How chronic obstructive pulmonary disease increases risk of lung cancer

July 24, 2012

In addition to the well-known risk factor of smoking, chronic obstructive pulmonary disease (COPD) increases lung cancer risk.

A University of Colorado Cancer Center study published in the journal details one novel mechanism of this risk: long-term stimulates signals that promote tumor growth. In addition, this early study – performed in animal models – shows that tumors fueled by these COPD-induced signals may be especially susceptible to prevention or perhaps even treatment with drugs that turn off these same signals, namely VEGFR-2 and EGFR inhibitors.

"At least in animal models, this study shows an important pathway activated in lung tumors arising in poorly oxygenated regions of the lung that isn't activated to nearly the same degree in other lung cancers," says York Miller, MD, investigator at the CU Cancer Center and professor in the Department of Pulmonary Sciences and Critical Care Medicine at the University of Colorado School of Medicine and Denver Veterans Affairs Medical Center, the paper's senior author.

"There are probably other mechanisms driving in COPD as well – for example, inflammation is also very likely playing in – but this paper shows that the hypoxic sensing pathway is specifically activated in these COPD lung cancer models and that this sensing pathway is to a large degree driving tumor growth," Miller says.

Specifically, his study used animal models designed to develop cancer, which the group placed in high altitude chambers set to mimic the chronic oxygen depletion of found in parts of the lung affected by COPD. Mice in the hypoxic condition developed larger tumors than mice given normal oxygen, but, according to Miller, what was especially striking is the reason for this tumor growth.

"We saw that in the hypoxic environment – which mimics that of COPD conditions including chronic bronchitis and emphysema – is due to signaling by HIF-2a. This HIF-2a in turn activates cancer growth promoting mechanisms including VEGF and the EGFR ligand, TGFa, which are growth factors involved in stimulating cell proliferation and the development of new blood vessels," Miller says.

Likewise, just as tumors that arise in hypoxic conditions do so through turning on pathways that lead to the over-production of VEGF and TGFa, so too are these tumors especially susceptible to cancer therapies that block these growth factors. Sure enough, animal models given the drug vandetanib – a combined VEGFR/EGFR inhibitor – failed to develop cancer under hypoxic conditions.

"Chemoprevention hasn't been done successfully for lung cancer," Miller says, "but this approach of VEGF/EGFR inhibitors for patients with COPD and extreme lung cancer risk may be something that should be explored further."

Miller imagines the next step is a review of patient records to discover if COPD lung cancer patients who happened to be treated with VEGF/EGFR inhibitors, in fact, had better tumor response than patients with normal lung function and similar tumors.

"Right now it's not a treatment," Miller says, "but it's an exciting line of inquiry."

Explore further: Early COPD detection could help lung cancer diagnosis

Related Stories

Early COPD detection could help lung cancer diagnosis

November 16, 2011
Early screening of patients with chronic obstructive pulmonary disease (COPD) may help to detect lung cancer at an earlier stage, according to a new study.

The right combination: Overcoming drug resistance in cancer

June 1, 2012
Overactive epidermal growth factor receptor (EGFR) signaling has been linked to the development of cancer. Several drug therapies have been developed to treat these EGFR-associated cancers; however, many patients have developed ...

The link between TB and a gene mutation that causes lung cancer

January 18, 2012
Tuberculosis (TB) has been suspected to increase a person's risk of lung cancer because the pulmonary inflammation and fibrosis can induce genetic damage. However, direct evidence of specific genetic changes and the disease ...

SBRT provides better outcomes than surgery for cancer patients with common lung disease

February 16, 2012
Stereotactic body radiotherapy (SBRT) provides better overall survival rates than surgery for lung cancer patients with severe chronic obstructive pulmonary disease (COPD), a disease commonly associated with lung cancer, ...

High VEGF signaling score tied to lung cancer prognosis

February 22, 2012
(HealthDay) -- A high vascular endothelial growth factor (VEGF) signaling score correlates with good prognosis in patients with early squamous cell carcinoma (SCC) of the lung, according to a study published online Feb. 21 ...

Recommended for you

Study prompts new ideas on cancers' origins

December 16, 2017
Rapidly dividing, yet aberrant stem cells are a major source of cancer. But a new study suggests that mature cells also play a key role in initiating cancer—a finding that could upend the way scientists think about the ...

What does hair loss have to teach us about cancer metastasis?

December 15, 2017
Understanding how cancer cells are able to metastasize—migrate from the primary tumor to distant sites in the body—and developing therapies to inhibit this process are the focus of many laboratories around the country. ...

Cancer immunotherapy may work better in patients with specific genes

December 15, 2017
Cancer cells arise when DNA is mutated, and these cells should be recognized as "foreign" by the immune system. However, cancer cells have found ways to evade detection by the immune system.

Scientists pinpoint gene to blame for poorer survival rate in early-onset breast cancer patients

December 15, 2017
A new study led by scientists at the University of Southampton has found that inherited variation in a particular gene may be to blame for the lower survival rate of patients diagnosed with early-onset breast cancer.

Scientists unlock structure of mTOR, a key cancer cell signaling protein

December 14, 2017
Researchers in the Sloan Kettering Institute have solved the structure of an important signaling molecule in cancer cells. They used a new technology called cryo-EM to visualize the structure in three dimensions. The detailed ...

'Bet hedging' explains the efficacy of many combination cancer therapies

December 14, 2017
The efficacy of many FDA-approved cancer drug combinations is not due to synergistic interactions between drugs, but rather to a form of "bet hedging," according to a new study published by Harvard Medical School researchers ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.